PL2265279T3 - Zastosowanie nonapeptydu pat w leczeniu chorób autoimmunologicznych - Google Patents

Zastosowanie nonapeptydu pat w leczeniu chorób autoimmunologicznych

Info

Publication number
PL2265279T3
PL2265279T3 PL09761861T PL09761861T PL2265279T3 PL 2265279 T3 PL2265279 T3 PL 2265279T3 PL 09761861 T PL09761861 T PL 09761861T PL 09761861 T PL09761861 T PL 09761861T PL 2265279 T3 PL2265279 T3 PL 2265279T3
Authority
PL
Poland
Prior art keywords
nonapeptide
pat
treatment
autoimmune diseases
autoimmune
Prior art date
Application number
PL09761861T
Other languages
English (en)
Inventor
Jamal Temsamani
Claude Laruelle
Original Assignee
Cll Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cll Pharma filed Critical Cll Pharma
Publication of PL2265279T3 publication Critical patent/PL2265279T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL09761861T 2008-04-21 2009-04-15 Zastosowanie nonapeptydu pat w leczeniu chorób autoimmunologicznych PL2265279T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0802220A FR2930156B1 (fr) 2008-04-21 2008-04-21 Utilisation du nonapeptide pat dans le traitement des maladies autoimmunes.
PCT/FR2009/000439 WO2009150310A1 (fr) 2008-04-21 2009-04-15 Utilisation du nonapeptide pat dans le traitement de maladies autoimmunes
EP09761861.5A EP2265279B1 (fr) 2008-04-21 2009-04-15 Utilisation du nonapeptide pat dans le traitement de maladies autoimmunes

Publications (1)

Publication Number Publication Date
PL2265279T3 true PL2265279T3 (pl) 2015-05-29

Family

ID=40024222

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09761861T PL2265279T3 (pl) 2008-04-21 2009-04-15 Zastosowanie nonapeptydu pat w leczeniu chorób autoimmunologicznych

Country Status (6)

Country Link
US (1) US9427455B2 (pl)
EP (1) EP2265279B1 (pl)
JP (1) JP5536037B2 (pl)
FR (1) FR2930156B1 (pl)
PL (1) PL2265279T3 (pl)
WO (1) WO2009150310A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2962335B1 (fr) * 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
US9468662B2 (en) 2010-07-12 2016-10-18 Orphit Use of the PAT nonapeptide in the treatment and prevention of neurodegenerative diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7502830A (nl) * 1974-03-25 1975-09-29 Jean Francois Bach En Dr Jean Werkwijze voor het isoleren van een polypeptide hormoon.
US4098777A (en) * 1977-03-14 1978-07-04 Merck & Co., Inc. Process for the preparation of pyroglutamyl-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn
GB1572889A (en) * 1977-05-25 1980-08-06 Inst Nat Sante Rech Med Polypeptides
GR75636B (pl) * 1980-05-22 1984-08-02 Inst Nat Sante Rech Med
JPS5852225A (ja) 1981-09-22 1983-03-28 Mitsui Pharmaceut Inc 脱髄疾患治療剤
US5808009A (en) * 1996-09-23 1998-09-15 North Dakota State University Research Foundation Method of affinity purifying antibodies
FR2830451B1 (fr) * 2001-10-09 2004-04-30 Inst Nat Sante Rech Med Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur

Also Published As

Publication number Publication date
WO2009150310A1 (fr) 2009-12-17
JP5536037B2 (ja) 2014-07-02
JP2011518212A (ja) 2011-06-23
US20110098223A1 (en) 2011-04-28
EP2265279A1 (fr) 2010-12-29
US9427455B2 (en) 2016-08-30
FR2930156A1 (fr) 2009-10-23
FR2930156B1 (fr) 2011-10-28
EP2265279B1 (fr) 2014-10-22

Similar Documents

Publication Publication Date Title
IL243538B (en) Artificial triterpenoids and methods for use in the treatment of disease
IL247183B (en) Secretory-apoptosis factors for the treatment of cancer and immune and autoimmune diseases
IL208845A (en) Progesterone antagonists such as 4124 CDB in the treatment of breast cancer
IL218851A0 (en) Use of dimiracetam in the treatment of chronic pain
PT2320900T (pt) Utilização de opioides ou miméticos de opioides para o tratamento de pacientes com cancros resistentes
GB2460178B (en) Depsipeptides and their therapeutic use
GB2460181B (en) Depsipeptides and their therapeutic use
SI2491005T1 (sl) Uporaba 4-(etil(dimetil)amonio)butanoata pri zdravljenju bolezni srca in oĺ˝ilja
GB0905970D0 (en) Depsipeptides and their therapeutic use
IL216717A0 (en) USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES
PL2265279T3 (pl) Zastosowanie nonapeptydu pat w leczeniu chorób autoimmunologicznych
GB2460180B (en) Depsipeptides and their therapeutic use
PL2593129T3 (pl) Nonapeptyd pat do stosowania w leczeniu choroby alzheimera
GB0809328D0 (en) Depsipeptides and their therapeutic use
GB0809324D0 (en) Depsipeptides and their therapeutic use
GB0809326D0 (en) Depsipeptides and their therapeutic use
GB0809330D0 (en) Depsipeptides and their therapeutic use
GB201015789D0 (en) Peptides and their use in the treatment
GB0904043D0 (en) The treatment of raynaud's phenomenon
GB0820562D0 (en) Novel use and treatment
GB0814920D0 (en) Peptides and their use in treatment